Earticle

초록

영어

Background: Patients with chronic kidney disease (CKD) are at a high risk of stroke-related morbidity, mortality, and bleeding. However, the overall risk/benefit of anticoagulant therapy among patients with CKD remains unclear. Methods: The MEDLINE, EMBASE, and CENTRAL databases were comprehensively searched until July 31, 2020, to investigate the safety and efficacy of apixaban in patients with stage 4 or 5 CKD, as compared with warfarin. The primary outcome was an incidence of major bleeding. Secondary outcomes included composite bleeding (major, clinically relevant, and minor bleeding), venous thromboembolism (VTE), stroke, and death. Results: In total, seven studies consisting of 10,816 patients were included. Compared with warfarin, apixaban was associated with a reduced risk of major bleeding (OR 0.49, 95% CI 0.41-0.58). In terms of composite bleeding, apixaban tended to pose a significantly lower risk than warfarin (OR 0.51, 95% CI 0.37-0.71). There was no difference between apixaban and warfarin with respect to the risk of stroke or death (stroke: OR 1.23, 95% CI 0.49-3.12; death: OR 0.73, 95% CI 0.45- 1.18). Conclusion: Among patients with stage 4 or 5 CKD, the use of apixaban was associated with a lower risk of bleeding compared to warfarin and was also found to pose no excess risk of thromboembolic events.

목차

ABSTRACT
연구 방법
문헌 검색
문헌 선택
자료 추출
비뚤림 평가
자료의 통합 및 분석
연구 결과
문헌 선택 결과
체계적 문헌고찰 대상문헌들의 개별적 특성
Major bleeding 발생률
Composite bleeding 발생률
Stroke 및 VTE 발생률
사망률
선정 문헌의 비뚤림 위험 평가
고찰
결론
감사의 말씀
이해상충
참고문헌

키워드

저자

• 남재현 [ Jae Hyun Nam | 한양대학교 약학대학, 한양대학교 서울병원 ]
• 김채영 [ Chae Young Kim | 한양대학교 약학대학 ]
• 이유경 [ Yoo Kyung Lee | 한양대학교 약학대학 ]
• 정다움 [ Da Woom Jung | 한양대학교 약학대학 ]
• 곽혜영 [ Hye Young Gwak | 한양대학교 서울병원 ]
• 정지은 [ Jee Eun Chung | 한양대학교 약학대학 ] Corresponding Author

참고문헌

발행기관

간행물

표지보기 관심저널 등록

• 간행물명

  한국임상약학회지 [Korean Journal of Clinical Pharmacy]

• 간기

  계간

• pISSN

  1226-6051

• 수록기간

  1991~2026

• 등재여부

  KCI 등재

• 십진분류

  KDC 518 DDC 615